Medical News Feed
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
| Drug class description : | 5HT1 -agonists. |
| Generic Name : | Sumatriptan |
| Drug description : | Imigran Subject: pre-filled syringes plus autoinjector. Imigran Tablets: pink or white elongated f-c tablets marked with tablet name and strength. Imigran Nasal Spray: single dose nasal spray. |
| Presentation : | Imigran Subject: Sumatriptan (as succinate) 6mg per 0.5mL. Imigran Tablet: Sumatriptan (as succinate) 50 mg , 100 mg . Imigran Nasal Spray: Sumatriptan 20mg per 0.1mL. |
| Indications : | Imigran Subject: Acute treatment of migraine, with or without aura, or cluster headaches, only where there is a clear diagnosis. Imigran Tablets and Imigran Nasal Spray: Acute migraine attacks, with or without aura, only where there is a clear diagnosis. |
| Adult Dosage : | Imigran Subject: 6 mg by subcutaneous injection soon after onset of attack. If migraine recurs in patients who respond, repeat after minimum 1 hour. Maximum 12 mg in 24 hours. Imigran Tablets: 50 - 100 mg soon after onset of attack. If migraine recurs in patients who respond, repeat dose. Dose should not exceed 300 mg in 24 hours. Patients who fail to respond initially should not receive a second dose for same attack. Imigran Nasal Spray: Over 18 years, 1 spray into one nostril soon after onset of attack. If migraine recurs in dose may be given at an interval of at least 2 hours. Dose should not exceed 2 x 20 mg in 24 hours. Patients who fail to respond initially should not receive a second dose for same attack. |
| Child Dosage : | Not recommended in patients under 18. |
| Elderly Dosage : | Experience in the use of Imigran in patients over 65 years is limited. Use in the over 65s is not recommended. |
| Contra Indications : | Ischaemic heart disease, previous myocardial infarction, Prinzmetal's angina, uncontrolled hypertension, coronary vasospasm. |
| Special Precautions : | Cardiac disease, risk factors of coronary artery disease; assess patients before initiating therapy. History of epilepsy or brain lesions, hepatic or renal impairment. Sensitivity to sulphonamides. Pregnancy, lactation. Driving or operating machinery. |
| Interactions : | MAOIs, 5-HT re-uptake inhibitors, lithium, ergotamine. |
| Adverse Reactions : | Pain, sensation of heaviness or pressure, fatigue, dizziness, drowsiness, weakness, increases in BP. Minor disturbances of liver function tests. Rarely, seizures, hypotension, bradycardia, serious coronary events. Hypersensitivity reactions. Pain at inj. site. Transient bitter taste with spray. If angina-like symptoms (transient chest pain or throat symptoms) occur, withdraw treatment and investigate cause immediately. |
| Manufacturer : | GlaxoSmithKline(GSK) |
| Drug Availability : | (POM) |
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org